• Home
  • A-B index
  • Pharmacological Index
  • Drug Classes
  • Active Ingredients
  • Companies
  • News
  • Zappa
    / Unipharm


    Active Ingredient
    Olanzapine 5, 7.5, 10 mg

    Status in Israel
    RX

    Presentation and Status in Health Basket

    Presentation Basket Yarpa Pharmasoft

    Film Coated Tablets

    30 X 5 mg

    partial basket chart 13466 26189

    Film Coated Tablets

    60 X 7.5 mg

    partial basket chart 13488 26190

    Film Coated Tablets

    30 X 10 mg

    partial basket chart 13487 26188

    Orodispersible Tablets

    30 X 5 mg (ZAPPA ODT)

    partial basket chart 47259 26184

    Orodispersible Tablets

    30 X 10 mg (ZAPPA ODT)

    partial basket chart 47262 26185

    Related information


    Dosage

    Initial, maintenance: 10 mg daily.
    Adjust in range: 5-20 mg dailly.
    Method of administration: Zappa 5 and Zappa 10: If necessary, the tablet can be halved for immediate use. There is no information about crushing or chewing the tablet. Swallow the medicine with a little water.
    Zappa 7.5: Do not halve the tablet. There is no information about crushing or chewing the tablet. Swallow the tablet with a little water.
    See prescribing information for full details.


    Indications

    Schizophrenia: Acute monotherapy: Treatment of acute mixed or manic episodes associated with Bipolar I Disorder.
    Preventing recurrence in bipolar disorder: In patients whose manic episodes have responded to olanzapine treatment, therapy is indicated for the prevention of recurrence in patients with Bipolar Disorder.


    Contra-Indications

    Known hypersensitivity to the product.
    Risk of narrow-angle glaucoma-type (increased intraocular pressure) eye problems.


    Special Precautions

    Neuroleptic malignant syndrome has been reported in association with administration of antipsychotic drugs, including olanzapine.
    Tardive dyskinesia, potentially irreversible, may develop in patients treated with antipsychotic drugs. Should be prescribed in a manner that is most likely to minimize the occurence of tardive dyskinesia.
    May induce orthostatic hypotension.
    Patients with known cardiovascular disease (history of myocardial infarction or ischemia, heart failure, or conduction abnormalities), cerebrovascular disease, and conditions which would predispose patients to hypotension.
    Should be used cautiously in patients with a history of seizures or with conditions that potentially lower the seizure threshold.
    As with other drugs that antagonize dopamine D2 receptors, olanzapine elevates prolactin levels, and a modest elevation persists during chronic administration.
    The possibility of suicide attempt is inherent in schizophrenia and in bipolar disorder, and close supervision of high-risk patients should accompany drug therapy.
    See prescribing information for full details.


    Side Effects

    Schizophrenia: Postular hypotension, constipation, weight gain, dizziness, personality disorder, akathisia.
    Bipolar mania: Asthenia, dry mouth, constipation, dyspepsia, increased appetite, somnolence, dizziness, tremor.
    See prescribing information for full details.


    Drug interactions

    Alcohol, CNS depressants, cimetidine, disulfiram, carbamazepine, levodopa.
    See prescribing information for full details.


    Pregnancy and Lactation

    Pregnancy: Neonates may develop withdrawal syndrome if the mother has taken the medicine during the last trimester (the last three months) of pregnancy. The withdrawal syndrome includes the following symptoms: restlessness, tremor, muscle stiffness/weakness, sleepiness, nervousness,
    respiratory and feeding problems.
    Lactation: This medicine is not for use during lactation.


    Manufacturer
    Trima Israel Pharmaceutical Products Maabarot Ltd. Israel
    CLOSE